2026-527022-13-00RecruitingPhase 1
A clinical trial of MK-8210 in healthy participants (MK-8210-001)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- First submitted
- 8 Jul 2026
- Start date
- 24 Aug 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- EU CT number
- 2026-527022-13-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 88
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults to test MK-8210. The record lists HIV-1 as the condition studied.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.